New research provides hope for childhood cancer sufferers

Dr Richard Lock, Head of the Leukaemia Biology Program at the Children’s Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.

ALL is the most common form of childhood cancer. Over the years, improvements in primary therapy have increased the cure rate to approximately 80 percent. However, for the 20 percent of patients who relapse, the majority will die.

“When used in combination with common drugs administered in ALL therapy, ABT-737 has the ability to enhance the combined toxicity of these drugs against the leukaemia cells with minimal effects on the normal cells of the body,” said Dr Lock.

Resistance to common therapeutic drugs is associated with poor long-term outcomes in leukaemia patients. In the study, the effects of ABT-737 in combination with three common chemotherapeutic agents: L-Asparaginase, vincristine and dexamethasone, were tested on a number of ALL cell lines under conditions which were considered clinically relevant for the disease.

ABT-737, developed by Abbott Laboratories, acts by inhibiting the Bcl-2 family of proteins. These proteins are expressed in ALL and inhibit the mechanisms responsible for destroying leukaemia cells. High levels of expression of Bcl-2 is linked with chemoresistance in a variety of cancers.

“There is a critical need for new drugs with novel mechanisms of action that might improve the outcome for relapsed ALL patients,” said Dr Lock.

Source: Research Australia

Related stories:

Scientists identify childhood brain cancer genes
Scientists at The University of Nottingham have isolated three important genes involved in the development of a type of childhood brain cancer. The breakthrough is revealed in a study published in the British Journal of Cancer today.
Marine organisms could hold the secret to reducing cancer
Research into why a tea derived from an ancient crop from the western Pacific could be responsible for reducing the risk of cancer, is being conducted by Aberdeen experts.
Discovery major step forward in treating leukemia
Researchers at the University of East Anglia have discovered for the first time a pathway that makes cancerous leukaemia cells resistant to treatment.
New research provides hope for childhood cancer sufferers
Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.
Scientists close in on method to fight deadly childhood cancer
A multicenter team of researchers, including scientists from the University of Florida, has discovered a way to potentially block the growth of neuroblastoma, a type of cancer responsible for 15 percent of all cancer deaths in children.
Brain-nourishing molecule may predict schizophrenia relapse
A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.
Had an angioplasty? Maybe it wasn't needed
Most elective angioplasties, including those in Wisconsin, are done without checking to see whether they are needed by doing a non-invasive stress test, an analysis has found.
Tribendimidine shows promise against intestinal worms
Researchers have reported positive results from a safety and efficacy study pertaining to tribendimidine, a broad-based treatment for intestinal worm infections. The group's results demonstrate the success of the new drug from China versus that of the standard albendazole for the treatment of hookworm, large roundworm, whipworm, and, for the first time, threadworm and tapeworm.

News discussion:

Medicine & Health news